Apoptosis

How Apoptosis Works

Apoptosis proceeds through well-defined stages:

1. Initiation - Death signals activate intrinsic or extrinsic pathways
2. Execution - Caspase cascade begins proteolytic breakdown
3. Degradation - DNA fragmentation, organelle breakdown
4. Packaging - Cell fragments into apoptotic bodies
5. Clearance - Phagocytes engulf debris without inflammation

This controlled process takes approximately 30 minutes to several hours.

Relevance to Peptides

Several peptides modulate apoptotic pathways:

Pro-Apoptotic Peptides

• FOXO4-DRI - Induces apoptosis specifically in senescent cells
• Cancer-targeting peptides - Designed to trigger tumor cell death

Anti-Apoptotic/Cytoprotective Peptides

• Humanin - Protects neurons from amyloid-induced apoptosis
• BPC-157 - May reduce apoptosis in damaged tissues
• Thymosin alpha-1 - Modulates apoptosis in immune cells

Apoptosis Research Applications

Understanding apoptosis is crucial for:

• Cancer therapy peptides
• Neuroprotective peptide research
• Tissue repair and regeneration studies
• Senolytic development

Apoptotic Pathways

Pathway	Trigger	Key Players	Example Peptide Targets
Extrinsic	Death receptors (Fas, TRAIL)	Caspase-8	Death receptor ligands
Intrinsic	Mitochondrial damage, stress	Caspase-9, cytochrome c	Humanin (protective)
Perforin/granzyme	Cytotoxic immune cells	Granzyme B	Immune peptides

Apoptosis vs Other Cell Death

Feature	Apoptosis	Necrosis	Autophagy
Process	Programmed	Uncontrolled	Self-eating
Inflammation	Minimal	Significant	Variable
Energy requirement	ATP needed	ATP depleted	ATP needed
Membrane integrity	Maintained	Ruptured	Maintained
Outcome	Clean removal	Tissue damage	Survival or death

Caspase Cascade

Caspases are the executioner enzymes of apoptosis:

Initiator Caspases

• Caspase-8 (extrinsic pathway)
• Caspase-9 (intrinsic pathway)
• Activated by death signals

Executioner Caspases

• Caspase-3, -6, -7
• Cleave cellular substrates
• Cause characteristic apoptotic changes

Apoptosis in Disease

Condition	Apoptosis Status	Research Implication
Cancer	Deficient	Restore apoptosis
Neurodegeneration	Excessive	Protect from apoptosis
Autoimmune disease	Deficient in self-reactive cells	Induce apoptosis
Heart failure	Excessive cardiomyocyte death	Cardioprotection
Aging	Imbalanced	Senolytic approaches

Frequently Asked Questions

How is apoptosis different from senescence?

Senescent cells stop dividing but remain alive and metabolically active, secreting inflammatory factors (SASP). Apoptotic cells die and are cleared by the immune system. Senolytics like FOXO4-DRI work by converting senescent cells from survival to apoptosis.

Can peptides both promote and prevent apoptosis?

Yes, depending on the context and target tissue. FOXO4-DRI promotes apoptosis in senescent cells (beneficial), while humanin prevents apoptosis in neurons exposed to toxic proteins (also beneficial). The goal is restoring appropriate apoptotic balance.

Why don’t cancer cells undergo apoptosis?

Cancer cells often have mutations in apoptotic pathways (p53, BCL-2 family, caspases) that allow them to evade programmed cell death. Many cancer treatments aim to restore apoptotic sensitivity. Some peptide-based cancer therapies target these resistance mechanisms.

Is apoptosis always beneficial?

No. Appropriate apoptosis removes damaged and potentially dangerous cells. However, excessive apoptosis contributes to neurodegenerative diseases, heart failure, and tissue damage. The balance between too much and too little apoptosis is critical for health.